{"id":11083,"date":"2026-10-29T05:16:02","date_gmt":"2026-10-29T09:16:02","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11083"},"modified":"2026-10-29T05:41:23","modified_gmt":"2026-10-29T09:41:23","slug":"hydreight-explodes-by-12-percent-and-medicure-has-many-times-larger-upside","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/hydreight-explodes-by-12-percent-and-medicure-has-many-times-larger-upside\/","title":{"rendered":"Hydreight Explodes by 12.32% and Medicure Has Many Times Larger Upside"},"content":{"rendered":"\n<div style=\"width:100%; max-width:650px; margin:0 auto; padding:0 10px; box-sizing:border-box; font-family:Arial,Helvetica,sans-serif; font-size:14px; line-height:1.6; color:#333333; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; text-size-adjust:100%; mso-line-height-rule:exactly; display:block;\">\n<p style=\"margin:0 0 16px; padding:0; font-size:14px; line-height:1.6;\">Prior to our discovery of <strong>Medicure (TSXV: MPH)<\/strong> our last telehealth play was <strong>Hydreight (TSXV:<\/strong> <strong>NURS)<\/strong> and it <span style=\"color:#27ae60;\"><strong>gained by 12.32%<\/strong><\/span> yesterday to <strong>$3.52 per share<\/strong>. At its November high of <strong>$5.59 per share<\/strong>, it was <span style=\"color:#27ae60;\"><strong>up by 377.78%<\/strong><\/span> from our suggestion price of <strong>$1.17 per share<\/strong>. <strong>We believe Medicure&#8217;s <span style=\"color:#27ae60;\">upside<\/span> is <span style=\"color:#27ae60;\">many times larger<\/span>. <\/strong>The <strong>NASDAQ Biotech Index (IBB)<\/strong> just hit a <span style=\"color:#27ae60;\"><strong>new all-time high<\/strong><\/span> in afterhours trading. <strong>MPH<\/strong> has a <span style=\"color:#27ae60;\"><strong>100% chance<\/strong><\/span> of <span style=\"color:#27ae60;\"><strong>breaking out<\/strong><\/span> deep into <span style=\"color:#2980b9;\"><strong>double digits<\/strong><\/span> in the upcoming months. Our last biotech pick with Phase 3 trials <strong>Revive Therapeutics <span style=\"color:#27ae60;\">gained by 276%<\/span><\/strong> within two months of our suggestion and traded at a <strong>market cap<\/strong> of <span style=\"color:#27ae60;\"><strong>US$150 million+<\/strong><\/span> despite having a <span style=\"color:#e74c3c;\"><strong>0% chance<\/strong><\/span> of <span style=\"color:#2980b9;\"><strong>approval<\/strong><\/span> of a <strong>COVID-19 drug<\/strong> when <strong>COVID <span style=\"color:#e74c3c;\">didn&#8217;t<\/span><\/strong> even exist.<\/p>\n\n<p style=\"margin:0 0 16px; padding:0; font-size:14px; line-height:1.6;\"><span style=\"font-size:8px;\"><em>Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA&#8217;s President has purchased 87,000 shares of MPH and intends to buy more shares. NIA previously received compensation from NURS of US$30,000 cash for a three-month marketing contract which has since expired. NIA previously received compensation from Revive of US$30,000 cash for a three-month marketing contract which has since expired. This communication is for informational and educational purposes only.<\/em><\/span><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prior to our discovery of Medicure (TSXV: MPH) our last telehealth play was Hydreight (TSXV: NURS) and it gained by 12.32% yesterday to $3.52 per share. At its November high of $5.59 per share, it was up by 377.78% from our suggestion price of $1.17 per share. We believe Medicure&#8217;s upside is many times larger. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11085,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,28,414,10,311,8],"class_list":["post-11083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-etfs","tag-mph","tag-nurs","tag-rvv","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11083"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11083\/revisions"}],"predecessor-version":[{"id":11086,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11083\/revisions\/11086"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11085"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}